Vertex Pharmaceuticals (VRTX) Q3 2026 earnings review
Vertex sales rise 12%, but deal and launch costs cut profit
Vertex grew sales through its cystic fibrosis pills and gene therapy, yet launch spending and acquisition costs cut into profit. Revenue rose 12% to $3.44 billion, led by ALYFTREK and CASGEVY, while profit per share excluding one-offs dipped 1%. Chief executive Reshma Kewalramani raised the full-year revenue plan by $50 million, which only adds the newly acquired drug PALSONIFY and leaves fourth-quarter underlying growth slowing to 7% by our math.
| Sales from businesses owned a year ago | +11.5% total revenue $3.44B (+11.8% from a year ago) |
|---|---|
| Profit per share, excluding one-offs | $4.76 -0.8% from a year ago ($2.56 reported, -39%) |
| JOURNAVX revenue per prescription | $78 by our math, down from $93 last quarter |
| Full-year revenue outlook | Raised $50M adds $40–50M from acquired PALSONIFY |
⚖️ Verdict: 🔴 Bearish
The story got worse because diversification is adding costs and debt much faster than it adds revenue. The Crinetics buyout brought $4.5 billion of debt and lifted the full-year operating cost plan by $300 million excluding one-offs, while net revenue per JOURNAVX pain prescription fell to $78 by our math. One bright spot: CASGEVY reached $99 million in quarterly sales and the kidney pipeline stays on track for a November 30 FDA decision.
The question now is whether new launches can start paying for their commercial build-out in 2027. Either insurers begin paying normal prices for JOURNAVX and povetacicept wins approval to scale the kidney sales force, or heavy spending keeps profit flat while cystic fibrosis carries 95% of sales. The November 30 FDA decision and 2027 cost outlook next quarter will tell.
🐂 Bull Case
CASGEVY and ALYFTREK Carry Product Growth
Vertex is expanding its blood-disease gene therapy CASGEVY and shifting cystic fibrosis patients to its newer once-daily pill ALYFTREK. Both medicines grew fast this quarter and lifted total sales 12% to $3.44 billion. The company also gained reimbursement for ALYFTREK in seven more countries, bringing the total to 32, and won approval for CASGEVY in young children in the US, the UK and the Middle East.
- CASGEVY sales: $99.2 million, up 30% from last quarter and nearly six times a year ago
- ALYFTREK sales: $705.8 million, or 21.6% of cystic fibrosis sales by our math, up from 17.9% last quarter
- Older cystic fibrosis drug TRIKAFTA: $2.44 billion, down 8.2% from a year ago as patients switch
- Next-generation cystic fibrosis candidate VX-828: reduced sweat chloride by 6.6 to 9.4 mmol/L on top of TRIKAFTA in early testing
This matters because CASGEVY infusions are turning into steady revenue while ALYFTREK carries a lower royalty cost than TRIKAFTA. What to watch: fourth-quarter CASGEVY sales and the 2027 outlook for products outside cystic fibrosis, which will show whether gene-therapy infusions keep climbing without seasonal pauses.
Kidney Pipeline Advances Toward First Approval
Chief executive Reshma Kewalramani plans "to establish nephrology as our fifth commercial franchise" as US regulators review povetacicept, an antibody drug for the autoimmune kidney disease IgA nephropathy, ahead of a November 30 decision date. Beyond that review, the kidney pipeline hit two clinical milestones this quarter. Vertex completed full enrollment in the pivotal trial of inaxaplin, a pill for genetic APOL1-mediated kidney disease, and reported positive mid-stage data.
In that mid-stage study of patients with milder protein leakage or diabetes, inaxaplin cut urine protein levels by 25.4% to 44.7%, widening the drug's potential reach. What to watch: the FDA approval decision for povetacicept on November 30, 2026, and the pivotal interim readout for inaxaplin in early 2027, because approval and positive data would turn heavy kidney launch spending into a second major revenue pillar.
🐻 Bear Case
Launch Spending and Crinetics Deal Cut Profit
"Vertex delivered excellent third quarter results marked by strong revenue growth across the increasingly diversified portfolio, continued advancement of the R&D pipeline, and the successful close of the Crinetics Pharmaceuticals acquisition," chief executive Reshma Kewalramani said. Yet profit per share excluding one-offs slipped 0.8% from a year ago to $4.76, and reported net income fell 40% to $654 million after $502 million of acquisition costs.
Profit fell because Vertex raised commercial spending for its pain and kidney launches and bought Crinetics for $9.0 billion in net cash. Selling and general overhead excluding one-offs rose 4.2 percentage points of revenue to 16.2%, while research spending fell 0.8 points to 27.2%. To fund Crinetics, the biotech group also took on $4.5 billion in debt, raising quarterly interest expense from $3.3 million to $36.0 million.
What to watch: the 2027 operating expense outlook on the fourth-quarter call. Another year of double-digit cost growth to fund Crinetics trials and kidney sales teams would keep earnings flat even if new drugs grow.
JOURNAVX Price Per Prescription Keeps Sliding
JOURNAVX is Vertex's non-opioid pill for acute pain, and the company says it became the "most prescribed branded oral pain medicine in the U.S." in August. Doctors and hospitals filled more than 750,000 prescriptions in the third quarter, up more than 40% from last quarter. However, JOURNAVX revenue rose only 18% from last quarter to $58.3 million, meaning revenue is lagging behind volume.
By our math, Vertex collected at most $78 per prescription this quarter, down from $93 last quarter and $115 a year ago. Because patients still rely on free-drug assistance programs while insurers restrict coverage, rising volume is not yet paying for the commercial sales force. What to watch: fourth-quarter revenue per prescription, where a reading still below $80 would show that discounted access is dragging into 2027.
Revenue Outlook Raise Merely Adds Acquired Drug
Vertex raised its full-year revenue outlook by $50 million at the middle of the range, to between $13.15 billion and $13.25 billion. At the same time, it added $40 million to $50 million of expected sales from PALSONIFY, the acromegaly drug acquired with Crinetics on September 1. Stripping out that $45 million midpoint contribution leaves the outlook for businesses Vertex owned a year ago up just $5 million.
By our math, the full-year plan points to fourth-quarter underlying sales growth of 6.7%, down from 11.5% in the third quarter. What to watch: fourth-quarter cystic fibrosis sales against that implied 6.7% pace, which will show whether the core franchise is slowing or management is simply setting a low bar.
Risks this quarter didn't answer
Three standing business and pipeline risks received either a quiet timeline shift or no financial update in the third-quarter release.
- Type 1 diabetes delay: Vertex decided to "focus on accelerating the development of VX-017, which has the potential to reach more patients than zimislecel", pushing pivotal trials to 2027 and leaving zimislecel's regulatory filing unmentioned; watch the quarterly filing for any write-down.
- ALYFTREK royalty dispute: the release gave no update on Royalty Pharma's arbitration claiming an 8% royalty instead of 4% on $705.8 million of quarterly ALYFTREK sales; watch the legal footnote in the quarterly filing.
- Cystic fibrosis concentration: cystic fibrosis still generated 95.1% of third-quarter revenue; watch whether non-CF sales top 6% of revenue in the fourth quarter.
💲 Other KPIs
Net cash fell by more than half from $12.32 billion at year-end, by our math. Total cash and marketable securities dropped to $9.82 billion after $9.0 billion in net cash went to buy Crinetics, while Vertex borrowed $4.50 billion under a new term loan, including $1.00 billion due within a year.
Inventories rose 33.1% from $1,687 million at the end of 2025 and jumped 27.2% from last quarter alone. The increase reflects commercial stock for new launches including ALYFTREK, JOURNAVX and povetacicept, alongside acquired Crinetics inventory that carried a $5.4 million fair-value step-up charge this quarter.
Diluted shares fell 0.9% from 257.6 million a year ago and stayed flat against 255.2 million last quarter. Vertex continued to buy back stock during the first nine months of 2026, but the $9.0 billion Crinetics purchase and new debt load left the quarterly share count unchanged.
🔮 Guidance
Raised. The middle of the range moved up $50 million to $13.20 billion, or 10.0% growth for the year. By our math, that leaves fourth-quarter revenue growth at 7.8%, or 6.7% excluding PALSONIFY, down from 11.8% this quarter. It is the second raise this year (+$125M in Q2, +$50M in Q3) and still includes a 1.5 percentage point currency benefit.
Unchanged. The biotech group still expects at least $500 million combined from CASGEVY and JOURNAVX this year. After $355.4 million in the first nine months ($218.5 million from CASGEVY and $136.9 million from JOURNAVX), by our math the floor requires at least $144.6 million in the fourth quarter, below the third quarter's $157.5 million combined pace.
New. Following the September 1 close of the Crinetics acquisition, management expects $40 million to $50 million in PALSONIFY sales for the four months of ownership in 2026. After recording $10.1 million in September, by our math the middle of the range leaves $34.9 million for the fourth quarter, slightly above the September monthly run rate.
Raised. The cost plan moved up by $300 million at the middle of the range, to 17.2% growth for the year, driven by "operations and integration of Crinetics Pharmaceuticals for the remainder of 2026". By our math, that leaves $1,745 million of spending for the fourth quarter, a 28.1% jump from a year ago.
Raised. Reported operating expenses increased by $800 million at the middle of the range, to 23.8% growth over 2025. The increase adds the $300 million of ongoing Crinetics operating costs plus approximately $500 million of "compensation and transaction-related expenses associated with the Crinetics Pharmaceuticals acquisition" recorded in the third quarter.
Unchanged. The full-year tax rate plan stays at 19.5% to 20.5%. Because the rate excluding one-offs was 18.0% in the third quarter and 19.6% across the first nine months, meeting the middle of the full-year range points to a higher tax rate of roughly 21% in the fourth quarter.
❓ Key Questions
Why did JOURNAVX revenue per prescription drop below $78?
Prescriptions rose more than 40% from last quarter to over 750,000, but revenue grew only 18% to $58.3 million. Did channel inventory reverse after last quarter's build, or are more patients using free-drug assistance programs?
What is the status of the zimislecel diabetes submission?
Vertex shifted its Type 1 diabetes focus to accelerating VX-017 into pivotal trials in 2027 and dropped any mention of zimislecel timelines. Has the company shelved zimislecel after last year's manufacturing analysis?
What is Crinetics' annual expense run rate for 2027?
Adding four months of Crinetics operations lifted the 2026 operating cost outlook excluding one-offs by $300 million. How much of that increase is recurring research and commercial cost that will annualize to ~$900 million next year?
Where does the Royalty Pharma ALYFTREK arbitration stand?
ALYFTREK reached $705.8 million in quarterly sales, raising the stakes on whether Vertex owes a 4% or ~8% royalty. The release did not mention the dispute; when does management expect a ruling?